Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The LEAD-3 study found that liraglutide monotherapy reduced glycosylated hemoglobin (A1C), body weight, and blood pressure compared to glimepiride (36)
Currently, no federal law explicitly bars weight-based discrimination, and most federal appeals courts have held that obesity (unless caused by an underlying health condition) is not a protected disability under the ADA
Quantification of positive staining areas and Ki67-positive cells was performed using ImageJ software (NIH)
Pharmacologic considerations beyond the cholinergic sphere
US$ 28.26
US$ 27.57
US$ 22.55
US$ 24.06
